United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. Our lead product, Remodulin®, is approved in the U.S. and various countries around the world for both continuous subcutaneous and continuous intravenous infusion for the treatment of pulmonary arterial hypertension (PAH). In addition to prostacyclin analogs like Remodulin®, United Therapeutics develops Glycobiological Antiviral Agents for the treatment of infectious diseases, such as dengue and influenza. For more information about United Therapeutics' pipeline, click here
To receive press releases, quarterly and annual SEC filings, please click here.
Sep 8, 2014
2014 Morgan Stanley Global Healthcare Conference
Oct 1, 2014
Leerink Partners Rare Disease Roundtable